12月8日 - ** Kymera Therapeutics KYMR.O股价盘前上涨5.6%至70.32美元
** KYMR称， (link)，其实验性湿疹口服治疗药物在一项小型早期研究中缓解了症状和瘙痒，同时对哮喘或花粉症患者也有帮助。
** 该公司在 22 名中度至重度特应性皮炎患者中测试了 KT-621 药物，结果显示，患者的湿疹严重程度总体评分平均下降了 63%，瘙痒峰值下降了约 40%。
** Kymera公司称，KT-621的耐受性良好，没有严重的副作用，没有与治疗相关的安全问题，也没有其他湿疹药物曾出现过的眼部炎症病例。
** KYMR 股价今年以来上涨了 65.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.